Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis
The DOI matches its Crossref record, with a small difference in title or year; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background: Several pharmacologic options for type 2 diabetes are available. Purpose: To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes. Data Sources: Several databases from inception through 18 December 2019 and ClinicalTrials.gov on 10 April 2020. Study Selection: English-language randomized trials that had at least 24 weeks of intervention and assessed the effects of glucose-lowering drugs on mortality, glycemic, and vascular outcomes. Data Extraction: Pairs of reviewers extracted data and appraised risk of bias. Data Synthesis: 453 trials assessing 21 antidiabetic interventions from 9 drug classes were included. Interventions included monotherapies (134 trials), add-on to metformin-based therapies (296 trials), and monotherapies versus add-on to metformin therapies (23 trials). There were no differences between treatments in drug-naive patients at low cardiovascular risk. Insulin regimens and specific glucagon-like peptide-1 receptor agonists (GLP-1 RAs) added to metformin-based background therapy produced the greatest reductions in hemoglobin A1c level. In patients at low cardiovascular risk receiving metformin-based background treatment (298 trials), there were no clinically meaningful differences between treatments for mortality and vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background treatment (21 trials), oral semaglutide, empagliflozin, liraglutide, extended-release exenatide, and dapagliflozin reduced all-cause mortality. Oral semaglutide, empagliflozin, and liraglutide also reduced cardiovascular death. Odds of stroke were lower with subcutaneous semaglutide and dulaglutide. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduced heart failure hospitalization and end-stage renal disease. Subcutaneous semaglutide and canagliflozin increased diabetic retinopathy and amputation, respectively. Limitation: Inconsistent definitions of cardiovascular risk and low-level confidence in some estimates for patients at low cardiovascular risk. Conclusion: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes. Primary Funding Source: European Foundation for the Study of Diabetes, supported by an unrestricted educational grant from AstraZeneca. (PROSPERO: CRD42019122043)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a network meta-analysis of 453 trials assessing glucose-lowering medications from nine drug classes, the greatest reductions in HbA1c were seen with insulin regimens and GLP-1 RA (223).”
In the citing paper
“However, the comparative effectiveness of the two drug classes has been assessed in three recent network meta-analyses, which found that, in people with type 2 diabetes, SGLT2i were superior to GLP-1 RA in reducing HHF and a composite kidney outcome, while GLP-1 RA seemed more ef fi cacious in reducing the risk of stroke (223,259,260).”
In the citing paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
In the citing paper
“In a large systemic review and network analysis, including several GLP-1RAs, subcutaneous semaglutide was the only glucose-lowering drug for which this signal was observed”
From Safety of Semaglutide (2021) · cites this paper as [120]
In the citing paper
“A systematic review and meta-analysis of CGM use in adults with type 2 diabetes (12 randomized clinical trials with 1248 participants taking insulin, GLP-1RA, or oral glucose-lowering medications) reported that CGM led to a mean difference in HbA1C reduction over 10 to 34 weeks of −0.31% (95% CI, −0.43% to −0.19%) compared with BGM.49”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [49]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“ods (9), and report detailed methods in section 1 of the Supplement (available at Annals.”
MethodDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“On the basis of pairwise meta-analyses of cardiovascular outcome trials, compared with placebo, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiovascular death and stroke (4), whereas sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduce heart failure hospitalization (5) and end-stage renal disea…”
BackgroundChecking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“We evaluated consistency in the networks both locally by comparing direct with indirect evidence (19) and globally by using the design-by-treatment interaction model (20).”
MethodConsistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098 · cited 1×
“We evaluated consistency in the networks both locally by comparing direct with indirect evidence (19) and globally by using the design-by-treatment interaction model (20).”
MethodOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
CINeMA: an approach for assessing confidence in the results of a network meta-analysis
Nikolakopoulou, A., Higgins, J. P. T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., & Salanti, G. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003082 · Cited by 1,935
Research works printed but not linked: 1
- Schwarzer G, 2007, R news, 7, 40
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
“A recent systematic review and network meta-analysis suggests greatest reductions in A1C level with insulin regimens and specific GLP-1 RAs added to metformin-based background therapy (60).”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Flood, D., Seiglie, J. A., Dunn, M., Tschida, S., Theilmann, M., Marcus, M. E., Brian, G., Norov, B., Mayige, M. T., Gurung, M. S., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00089-1 · Cited by 277
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272
Self-citation9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Insulin resistance and insulin sensitizing agents
Mastrototaro, L., & Roden, M. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154892 · Cited by 254
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 204
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Xu, B., Li, S., Kang, B., & Zhou, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01512-w · Cited by 190
“Several meta-analyses have showed that SGLT-2 inhibitors lower the risk of all-cause mortality [12, 55, 59, 60, 95].”
BackgroundInfluentialTsapas, A., Karagiannis, T., Kakotrichi, P., Avgerinos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D. R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14451 · Cited by 179
“We did not include nodes with dual drug combinations and incorporated only treatment nodes of single agents in the network meta-analyses.(15) However, by means of how we defined background treatment (the antidiabetic medication therapy received in common both by intervention and control after randomization), certain t…”
BackgroundMethodInfluentialSelf-citationMetformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 171
Diabetic retinopathy: Screening, prevention, and treatment
Chong, D. D., Das, N., & Singh, R. P. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.24028 · Cited by 170
Metformin, Macrophage Dysfunction and Atherosclerosis
Feng, X., Chen, W., Ni, X., Little, P. J., Xu, S., Tang, L., & Weng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682853 · Cited by 164
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 150
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 160
Zou, R., Shi, W., Qiu, J., Zhou, N., Du, N., Zhou, H., Chen, X., & Ma, L. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01532-6 · Cited by 144
Stanciu, S. M., Rusu, E., Miricescu, D., Radu, A. C., Axinia, B., Vrabie, A.-M., Ionescu, R. F., Jinga, M., & Sîrbu, C. A. (2023) · Metabolites · doi:10.3390/metabo13010087 · Cited by 144
Mahtta, D., Ramsey, D. J., Lee, M. T., Chen, L., Al Rifai, M., Akeroyd, J. M., Vaughan, E. M., Matheny, M. E., Santo, K. R. D. E., Navaneethan, S. D., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1815 · Cited by 137
Qiu, M., Ding, L., Zhang, M., & Zhou, H. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211011016 · Cited by 123
Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G. (2021) · Cells · doi:10.3390/cells10081958 · Cited by 102
Advances in the management of type 2 diabetes in adults
Galindo, R. J., Trujillo, J. M., Wang, C. C. L., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000372 · Cited by 109
Lin, D. S.-H., Lee, J.-K., Hung, C.-S., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05529-w · Cited by 108
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024) · Diabetologia · doi:10.1007/s00125-024-06144-1 · Cited by 102
Self-citationSocioeconomic aspects of incretin-based therapy
Karagiannis, T., Bekiari, E., & Tsapas, A. (2023) · Diabetologia · doi:10.1007/s00125-023-05962-z · Cited by 91
“1 3 glucose-lowering and weight-reduction potential [42, 43], cardiovascular outcomes trials (CVOTs) have shown that GLP-1 RAs reduce cardiovascular outcomes (especially stroke) in people with elevated cardiovascular risk [42, 44, 45].”
BackgroundSelf-citationNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Yapislar, H., & Gurler, E. B. (2024) · Biomedicines · doi:10.3390/biomedicines12091958 · Cited by 64
(2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00240-0 · Cited by 67
Fatima, A., Rasool, S., Devi, S., Talha, M., Waqar, F., Nasir, M. I., Khan, M. R., Jaffari, S. M. I. A., Haider, A., Shah, S. U., et al. (2023) · Cureus · doi:10.7759/cureus.46243 · Cited by 83
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 85
Coronell‐Tovar, A., Pardo, J. P., Rodríguez‐Romero, A., Sosa‐Peinado, A., Vásquez-Bochm, L. X., Cano‐Sánchez, P., Álvarez‐Añorve, L. I., & González‐Andrade, M. (2024) · FEBS Letters · doi:10.1002/1873-3468.14901 · Cited by 78
Karakasis, P., Patoulias, D., Pamporis, K., Stachteas, P., Bougioukas, K. I., Klisic, A., Fragakis, N., & Rizzo, M. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155710 · Cited by 66
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 75
Eleftheriadou, A., Riley, D., Zhao, S. S., Austin, P., Hernández, G., Lip, G. Y. H., Jackson, T. L., Wilding, J. P. H., & Alam, U. (2024) · Diabetologia · doi:10.1007/s00125-024-06132-5 · Cited by 73
“A further systematic review and network meta-analysis suggested that canagli-flozin increased diabetic retinopathy, although this signal was not present for two other SGLT2is (empagliflozin and dapagliflozin) [23].”
BackgroundDrake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 74
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
“71,73 Another strength is represented by the retrieval of serious adverse events from multiple sources, that is, public trial repositories, and not only publications; this limits the possibility of publication bias.”
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“Notably, whereas SGLT2 inhibitors reduced heart failure hospitalisation, semaglutide and dulaglutide were associated with lower risk of stroke [61].”
BackgroundLamptey, R., Robben, M. P., Amoakoh‐Coleman, M., Boateng, D., Grobbee, D. E., Davies, M. J., & Klipstein‐Grobusch, K. (2022) · Diabetic Medicine · doi:10.1111/dme.14812 · Cited by 65
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Barkas, F., Şener, Y. Z., Golforoush, P. A., Kheirkhah, A., Rodríguez‐Sánchez, E., Novák, J., Apellániz-Ruiz, M., Akyea, R. K., Bianconi, V., Ceasovschih, A., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117579 · Cited by 65
Dennis, J., Young, K. G., Cardoso, P., Güdemann, L. M., McGovern, A. P., Farmer, A. A., Holman, R. R., Sattar, N. A., McKinley, T. J., Pearson, E. R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02617-5 · Cited by 65
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13960 · Cited by 60
Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
Ahmad, E., Sargeant, J. A., Zaccardi, F., Khunti, K., Webb, D. R., & Davies, M. J. (2020) · Pharmaceuticals · doi:10.3390/ph13120427 · Cited by 59
Young, K., McInnes, E. H., Massey, R. J., Kahkoska, A. R., Pilla, S. J., Raghavan, S., Stanislawski, M. A., Tobias, D. K., McGovern, A. P., Dawed, A. Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00359-w · Cited by 54
Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 51
Sun, H., Hao, Y., Liu, H., & Gao, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1525623 · Cited by 49
GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes
Li, P., Li, Z., Staton, E., Umpierrez, G. E., Davis, G. M., Shao, H., & Pasquel, F. J. (2024) · JAMA · doi:10.1001/jama.2024.18581 · Cited by 48
Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions
Wang, T., Zhou, D., & Hong, Z. (2025) · MedComm · doi:10.1002/mco2.70030 · Cited by 46
Alexander, J. T., Staab, E. M., Wan, W., Franco, M. I., KNITTER, A. C., Skandari, M. R., Bolen, S. D., Maruthur, N. M., Huang, E. S., Philipson, L. H., et al. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07105-9 · Cited by 46
Zhao, T., Yang, Q., Feuerbacher, J. F., Yu, B., Brinkmann, C. K., Cheng, S., Bloch, W., & Schumann, M. (2024) · British Journal of Sports Medicine · doi:10.1136/bjsports-2024-108127 · Cited by 45
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Moreover, compared with exenatide, liraglutide carries a lower risk of cardiovascular death [120].”
BackgroundMata‐Cases, M., Franch‐Nadal, J., Real, J., Vlacho, B., Gómez‐García, A., & Mauricio, D. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.02.003 · Cited by 44
Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Ntentakis, D. P., Correa, V., Ntentaki, A. M., Delavogia, E., Narimatsu, T., Efstathiou, N. E., & Vavvas, D. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06236-5 · Cited by 43
Johansen, M. E., & Argyropoulos, C. (2020) · Clinical Cardiology · doi:10.1002/clc.23508 · Cited by 43
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta‐analysis
Avgerinos, I., Karagiannis, T., Kakotrichi, P., Michailidis, T., Liakos, A., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14555 · Cited by 37
Self-citationDeng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., Lü, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03129-6 · Cited by 42
Chronic Kidney Disease in the Older Adult Patient with Diabetes
Ravender, R., Roumelioti, M., Schmidt, D. W., Unruh, M. L., & Argyropoulos, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020348 · Cited by 43
Cardoso, P., Young, K., Nair, A. T. N., Hopkins, R., McGovern, A. P., Haider, E., Karunaratne, P., Donnelly, L. A., Mateen, B. A., Sattar, N. A., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06099-3 · Cited by 42
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 41
Adipose tissue in older individuals: a contributing factor to sarcopenia
Wang, T., Zhou, D., & Hong, Z. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155998 · Cited by 40
Lin, D. S., Yu, A., Lo, H.-Y., Lien, C.-W., Lee, J., & Chen, W. (2022) · Diabetologia · doi:10.1007/s00125-022-05772-9 · Cited by 40
Joo, J. H., Sharma, N., Shaia, J., Wu, A. K., Skugor, M., Singh, R. P., & Rachitskaya, A. V. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100547 · Cited by 37
“If a dramatic decrease in blood glucose is truly the mechanism that drives paradoxical DR progression, 2,42,43 this would be consistent with the null fi ndings in this study.”
Rodionov, R. N., Peters, F., Marschall, U., L’Hoest, H., Jarzebska, N., & Behrendt, C. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2021.09.031 · Cited by 36
Singh, A. K., & Singh, R. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i6.329 · Cited by 35
Cronjé, H. T., Mi, M., Austin, T. R., Biggs, M. L., Siscovick, D. S., Lemaître, R. N., Psaty, B. M., Tracy, R. P., Djoussé, L., Kizer, J. R., et al. (2023) · Diabetes · doi:10.2337/db22-0628 · Cited by 34
Nephroprotective Properties of Antidiabetic Drugs
Gerdes, C., Muller, N., Wolf, G., & Busch, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103377 · Cited by 31
Abrilla, A. A., Pajes, A. N. N. I., & Jimeno, C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108824 · Cited by 31
McCoy, R. G., Herrin, J., Swarna, K. S., Deng, Y., Kent, D. M., Ross, J. S., Umpierrez, G. E., Galindo, R. J., Crown, W. H., Borah, B. J., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00453-9 · Cited by 30
Tsapas, A., Karagiannis, T., Avgerinos, I., Liakos, A., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108921 · Cited by 29
Self-citationShao, S., Chang, K., Lin, S., Chang, S., Hung, M., Chan, Y., & Lai, E. C. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01406-3 · Cited by 29
Chang, K.-C., Shao, S.-C., Kuo, S., Yang, C.-Y., Chen, H.-Y., Chan, Y.-Y., & Ou, H.-T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01148-8 · Cited by 28
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study
Deng, Y., Polley, E. C., Wallach, J. D., Dhruva, S. S., Herrin, J. S., Quinto, K., Gandotra, C., Crown, W. H., Noseworthy, P. A., Yao, X., et al. (2022) · BMJ · doi:10.1136/bmj-2022-070717 · Cited by 28
Hartanti, D., Chatsumpun, N., Kitphati, W., Peungvicha, P., & Supharattanasitthi, W. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14018 · Cited by 29
Peng, C. C., Tu, Y., Lee, G. Y., Chang, R. H., Huang, Y., Bukhari, K., Tsai, Y., Fu, Y., Huang, H., & Munir, K. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab353 · Cited by 28
Fadini, G. P., Bonora, B. M., Ghiani, M., Anichini, R., Melchionda, E., Fattor, B., Fazion, S., Meregalli, G., Giaccari, A., Avogaro, A., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15554 · Cited by 27
Emerging uncertainty on the anti-aging potential of metformin
Keys, M. T., Hallas, J., Miller, R. A., Suissa, S., & Christensen, K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102817 · Cited by 29
Wang, S., Wang, S., Wang, Y., & Luan, J. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01520-3 · Cited by 27
Tan, L., Wang, Z., Okoth, K., Toulis, K. A., Denniston, A. K., Singh, B. M., Crowe, F. L., Sainsbury, C. A. R., Wang, J., & Nirantharakumar, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1303238 · Cited by 26
New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11041159 · Cited by 25
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01121-x · Cited by 25
Pan, S., Su, E.-L., Huang, C., Chuang, S., Chiang, C., Chen, C., & Cheng, H. (2024) · Age and Ageing · doi:10.1093/ageing/afae175 · Cited by 25
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Diabetology International · doi:10.1007/s13340-022-00605-x · Cited by 23
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 23
Huggett, T. D., Tung, E. L., Cunningham, M. L., Ghinai, I., Duncan, H. L., McCauley, M., & Detmer, W. M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.38464 · Cited by 23
Scheen, A. J. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101474 · Cited by 22
Tilinca, M. C. (2023) · FARMACIA · doi:10.31925/farmacia.2023.4.4 · Cited by 22
Liu, T., Zhou, L., Chen, Y., Lin, J., & Zhu, H. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001896 · Cited by 22
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14202 · Cited by 22
Adamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 21
Li, Y., Gong, X., Găman, M., Hernández‐Wolters, B., Velu, P., & Li, Y. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14125 · Cited by 21
Hryciw, D. H., Patten, R. K., Rodgers, R. J., Proietto, J., Hutchinson, D. S., & McAinch, A. J. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2321271 · Cited by 21
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00723-8 · Cited by 21
Alexander, J. T., Staab, E. M., Wan, W., Franco, M. I., KNITTER, A. C., Skandari, M. R., Bolen, S. D., Maruthur, N. M., Huang, E. S., Philipson, L. H., et al. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07227-0 · Cited by 21
Tao, C., Zhang, Y., Wan, T., Zhao, W., Chen, J., Wang, K., Yang, L., Wang, G., Ding, Q., Shang, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1557691 · Cited by 20
Metadata
- Authors
- Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E.
- Affiliations
- Clinical Research and Evidence-Based Medicine Unit and Diabetes Centre, Aristotle University of Thessaloniki, Thessaloniki, Greece, and Harris Manchester College, University of Oxford, Oxford, United Kingdom (A.T.)
- Aristotle University of Thessaloniki (GR)
- Churchill Hospital (GB)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-08-18
- Volume
- 173
- Issue
- 4
- Pages
- 278-286
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3037508799
- Cited by
- 346
- References
- 34
- Citations by year
- 2026: 31 · 2025: 62 · 2024: 75 · 2023: 67 · 2022: 51 · 2021: 50 · 2020: 10
- FWCI
- 33.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Foundation for the Study of Diabetes (PAtient-Centred Treatment to support a holistic approach towards type 2 diabetes (PACT) Programme supported by an unrestricted educational grant from AstraZeneca)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, antidiabetic drugs, comparative effectiveness, metformin, GLP-1 receptor agonists, SGLT2 inhibitors, semaglutide, empagliflozin, liraglutide, dapagliflozin, canagliflozin, insulin, cardiovascular risk, all-cause mortality, cardiovascular mortality, stroke, heart failure hospitalization, end-stage renal disease, diabetic retinopathy, amputation, glycemic control, HbA1c, vascular outcomes, risk of bias
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.